Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Reminder to Shareholders regarding Unclaimed Dividends and Transfer to IEPF
Regulatory Filings Classification · 90% confidence The document is a regulatory compliance notice under SEBI LODR Regulation 30 informing the stock exchanges and shareholders of reminders for unclaimed dividends and impending transfer of shares to the IEPF. It is neither a new dividend declaration nor a financial report or management discussion, but a general regulatory announcement. Therefore, it falls under Regulatory Filings (RNS).
2026-06-01 English
General Updates
Regulatory Filings Classification · 90% confidence The document is an exchange and shareholder notice under SEBI (LODR) Regulation 30, reminding shareholders about unclaimed dividends and potential transfer to IEPF. It is a compliance announcement rather than a full financial report, earnings release, or dividend declaration. This falls under general regulatory announcements. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-06-01 English
Intimation of Effective Date for Scheme of Demerger involving Arco Lab Private Limited ("Arco Lab") and ("Pivot Path Private Limited").
Regulatory Filings Classification · 91% confidence The document is an intimation under Regulation 30 of the SEBI Listing Regulations sent to BSE and NSE announcing the effective date of a scheme of demerger. It does not contain financial statements, voting results, executive changes, or an actual report; rather, it is a regulatory announcement of a corporate action. This falls under the general regulatory filings/fallback category.
2026-06-01 English
General Updates
Regulatory Filings Classification · 91% confidence The document is a compliance announcement under Regulation 30 of the SEBI Listing Regulations notifying stock exchanges of the effective date of a Scheme of Demerger. It is not an Annual or Interim Report, nor earnings, proxy, or management discussion. It is a regulatory disclosure of a corporate restructuring event that does not fit other specific categories (e.g., M&A announcements for takeover bids or share issues). Therefore it is best classified as a general regulatory filing (RNS).
2026-06-01 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 81% confidence The document is an intimation under SEBI Listing Regulations to the stock exchanges regarding the schedule of Analyst/Institutional Investor non-deal roadshows. It merely notifies the exchange and public of upcoming investor meetings. It does not contain financial statements, the actual presentation materials, or constitute a report itself. It is a regulatory disclosure under listing rules, fitting the “Regulatory Filings” fallback category (RNS).
2026-05-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a stock exchange disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regarding the schedule of Analyst/Institutional Investor meetings. It does not contain financial results or detailed presentations itself, nor is it a request for votes, proxy materials, or an actual investor presentation. It is a compliance announcement informing the exchanges of an upcoming event and therefore falls under general regulatory filings.
2026-05-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.